Therapeutic Advances in
the Management of Hyperkalemia with
End Stage Renal Disease: Improving Clinical and Cost
Outcomes in an Evolving Treatment Paradigm
A continuing medical
education activity sponsored by NAMCP and AAMCN
This webinar series will provide critical updates on the advances in
of Hyperkalemia in patients with End Stage Renal Disease
These are archives of live webinars held between October 21 and
October 26, 2020.
If you participated in any of the live webinars, you are not
claim credit from the archive of that webinar.
By clicking on each of the titles, you will be able to participate
in each part.
It is not required that you participate in all 3 or in order.
These activities are valid from November 1, 2020 to November 1, 2022
series is supported by an educational grant from
This activity is intended for healthcare professionals practicing in managed
Instructions for CME/NCPD: Complete the pre-test,
listen to the audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your internet
browser without completing the post test, you will have ONE more opportunity to
complete. A score of 70% must be achieved on the post test to receive continuing
education credits. If you do not pass the post test after two attempts, you will
not be eligible to try again. Once you complete the evaluation form and score
70% or higher on your post test, you will automatically be given your
Hyperkalemia, also known has high potassium, is an elevated level of potassium
in the blood. Typically this results in no symptoms, but occasionally when
severe it results in palpitations, muscle pain, muscle weakness, or numbness.
Decreased kidney function is a major cause of hyperkalemia, especially in
chronic kidney disease (CKD). Hyperkalemia occurs in up to 10% of hospitalized
patients and is associated increased morbidity if left unaddressed. Fortunately
for patients who experience hyperkalemia, new therapies have become available in
recent years that have shown improved efficacy and safety. Attendees will be
updated on these novel options and how they can integrate them into the
treatment paradigm and optimize costs.